ArticleApplied clinical informatics2025
A Rash Decision: Implementing an EHR-Integrated Penicillin Allergy Delabeling Protocol without Adequate Clinician Support.
Article in Applied clinical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Approximately 10% of patients have a documented penicillin "allergy"; however, up to 95% have subsequent negative testing. These patients may receive suboptimal antibiotics, leading to longer hospitalizations and higher costs, rates of resistant and nosocomial infections, and all-cause mortality. To mitigate these risks in children, we implemented an inpatient penicillin allergy delabeling protocol and integrated it into the electronic health record (EHR) through a mixed methods approach of clinical decision support (CDS).We describe our protocol implementation across three sequential phases: "Pilot," "Active Antimicrobial Stewardship Program (ASP)," and "Mixed CDS." We highlight several potential pitfalls that may have contributed to poor clinician adoption.Patients were risk-stratified as nonallergic, low-risk, or high-risk based on history. Process measures included: evaluation rate, oral challenge rate for low-risk, and allergy referral rate for high- or low-risk when oral challenge was deferred. The primary outcome measure was the penicillin allergy delabeling rate among low-risk or nonallergic. Balancing measures included the rate of epinephrine or antihistamine administrations.The pilot and ASP phases used clinician education and an order set, but were mostly manual processes. The mixed CDS phase introduced interruptive alerts, dynamic text in note templates, and patient list columns to guide clinicians, but little education was provided. The mixed CDS phase had the lowest evaluation rate compared with the pilot and active ASP phases (6.4 vs. 25 vs. 15%). However, when the evaluation was performed, the mixed CDS phase had the highest oral challenge rate (33 vs. 26 vs. 13%) and delabeling rate (43 vs. 33 vs. 27%). No adverse events occurred.CDS tools improve clinician decision-making and optimize patient care. However, relying on CDS for complex clinical evaluations can lead to failure when clinicians cannot find the tool or appreciate its importance. Person-to-person communication can be vital in establishing a process and educating intended users for successful CDS implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.